ClinicalTrials.gg
CompletedNCT01623596PREFERMSUpdated Jan 5, 2021Results posted

Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.

A Phase 4 interventional study of Fingolimod and Disease Modifying therapy in Relapsing Remitting Multiple Sclerosis, sponsored by Novartis Pharmaceuticals. Completed at 123 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-01-05.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
881
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, 1 under way, none of them phase 3. fingolimod · Multiple Sclerosis, Relapsing-Remitting.

Enrollment
4th of 19
881 · median 142
Started
2012
with 3 others
Phase 4
14 of 19
none open now
Registered
11th of 19
by date
Lead sponsor
14 of 19
Novartis Pharmaceuticals

Among the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting, this one is the 4th largest by enrollment, is one of 4 that started in 2012, is one of 14 in phase 4, and was the 11th registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

None of the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →

About fingolimod

fingolimod: first FDA approval 2010 (GILENYA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 60 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 43 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting as a file.
02

Study summary

A 12 month study where 852 patients with relapsing remitting MS will be randomized 1:1 to fingolimod or approved disease modifying therapy. Patients will be be treatment naive or have only been treated with one class of DMT (Interferon beta preparation or glatiramer acetate) . Patients will be able to switch to different treatment for safety, efficacy, tolerability or convenience during the study.

Primary objective is to evaluate efficacy of fingolimod by assessing patients retention on treatment. Secondary objectives are to compare reasons for discontinuation, adverse events, cognitive impairment, medication satisfaction and change in brain volume measured by MRI.

Read the detailed description

852 Patients with relapsing remitting MS will be randomized 1:1 to fingolimod or approved first line DMTs. Patients must be either treatment naive or have received treatment with only one class of treatment (interferon beta preparation or glatiramer acetate) . Patients previously treated with DMT and randomized to the DMT arm may not remain on the same treatment for the study and will have to switch to a different class (i.e., previously treated with glatiramer acetate will switch to interferon beta preparaption, previously treated with interferon beta preparation will swtich to glatiramer acetate).

Entry criteria at screening include but are not limited to, age 18-65, diagnosis with RRMS, EDSS \< or equal to 6, not pregnant or planning pregnancy and women of childbearing potential willing to use contraception throughout the study.

Exclusion criteria include but are not limited to - prior exposure to fingolimod, history of malignancy within 5 years, other than RRMS types of MS, other diseases of the immune system, active macular edema, systemic bacterial, viral or fungal infections, patients without vaccine against varicella zoster, receipt of live or attentuated vaccines within a month of screening, history of various cardiac conditions, presence of certain ECG abnormalities, resting heart rate \< 45 bpm, symptomatic bradycardia, recurrent syncope, severe untreated sleep apnea, severe pulmonary conditions, various hepatic conditions, certain neurologic disorders, pregnancy.

Patients may switch treatment before 3 months for safety reasons only, after 3 months for safety, efficacy, tolerability or convenience. Treatment switch during the study may be to any of study approved treatments irrespective of prior treatment.

Patients randomized to fingolimod will need to have 6 hours of observation for signs and symptoms of bradycardia following administration of the first dose. Extended observation or overnight observation may be necessary under certain circumstances. Primary objective is to evaluate efficacy of fingolimod by assessing patients retention on treatment. Secondary objectives are to compare reasons for discontinuation, adverse events, cognitive impairment, medication satisfaction and change in brain volume measured by MRI. Exploratory objectives include annualized relapse rate, OCT, MRI evaluations, biomarkers and patient reported outcome measures.

03

Conditions studied

  • Relapsing Remitting Multiple Sclerosis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. written must be obtained prior to any assessment being performed.
  2. Male and female patients aged 18-65 years inclusive.
  3. Patients diagnosed with relapsing remitting MS, defined by the 2010 revised McDonald criteria (Pollman et al, 2011) (Appendix 1).
  4. EDSS score of less than or equal to 6.
  5. Patients naive to treatment or who have been treated with no more than one class of DMT previously (interferon β preparation or glatiramer acetate), and who, per investigator judgment, may benefit from a change of treatment class.
  6. Patients who have been treated with DMF for less than 2 months total exposure and who have a normal lymphocyte count at screening.
  7. Women of must have a negative urine and serum β-human chorionic gonadotropin (β-hCG) pregnancy test at screening and at baseline.
  8. Before entry women must be:

    • Post menopausal for at least 1 year, or
    • Surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation or otherwise incapable of pregnancy, or
    • Practicing a highly effective method of if sexually active, including hormonal prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double barrier method (e.g., condoms, diaphragm or cervical cap with spermicidal foam, cream or gel), or male partner sterilization consistent with local regulations regarding use of birth control methods for patients participating in clinical trials, for the duration of their participation in the study, or
    • Not heterosexually active (patients who are not heterosexually active at screening must agree to utilize a highly effective method of birth control if they become heterosexually active during their participation in the study) 4.2 Exclusion criteria

<!-- -->

  1. Use of other drugs within 30 days of screening.
  2. History of to any of the study drugs or to drugs of similar chemical classes.
  3. Prior exposure to fingolimod or any other S1P receptor modulating compounds.
  4. History or presence of of any organ system (other than successfully treated basal or squamous cell carcinoma of the skin or stage 0 carcinoma of the cervix), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or .
  5. Patients diagnosed with Secondary Progressive Multiple Sclerosis (SPMS) or Primary Progressive MS (PPMS).
  6. Patients with a history of chronic disease of the immune system other than MS or a known immunodeficiency syndrome.
  7. Patients who have been treated with:

    • Natalizumab, mitoxantrone, cladribine, rituximab, alemtuzumab, ofatumumab, ocrelizumab at any time before randomization
    • Immunoglobulins, or pulse of with more than 6 months cumulative exposure
    • /chemotherapeutic medications (e.g., methotrexate, azathioprine, cyclophosphamide, cellcept, Cytoxan, IVIG) with more than 6 months of cumulative exposure and within 6 months prior to randomization
    • Corticosteroids or adrenocorticotropic hormones in the past 30 days before randomization. Patients that require corticosteroids for a relapse during the screening period may be rescreened 30 days after the last dose.
  8. History of treatment with both classes of approved DMT (interferon β preparation and glatiramer acetate) or DMF exposure of 2 months or longer.
  9. Patients with uncontrolled diabetes mellitus ( > 7%).
  10. Diagnosis of macular edema during the screening phase. Patients with a history of macular edema will be allowed to enter the study provided that they do not have macular edema at the screening visit.
  11. Patients with active systemic bacterial, viral or fungal infections, or known to have AIDS, , infection or positive antibody, Hepatitis B surface antigen or Hepatitis C antibody tests.
  12. Patients without history of chickenpox or without vaccination against varicella-zoster virus at screening (patients may be vaccinated and rescreened one month or longer after vaccination).
  13. Patients who have received any live or (including for varicella-zoster or measles) within 1 month prior to baseline.
  14. Patients with any medically unstable condition as assessed by the investigator.
  15. Patients with a history of the following cardiovascular conditions:

    • Cardiac arrest.
    • myocardial infarction, unstable angina, stroke, , decompensated heart failure requiring hospitalization, or Class III/IV heart failure (Appendix 3).
    • Congestive heart failure.
    • Hypertension that is not controlled with prescribed medications. These patients may be rescreened if blood pressure is stabilized with treatment.
    • Cerebrovascular disease.
    • History or presence of Mobitz Type II 2nd degree or 3rd degree AV block or sick sinus syndrome, unless patient has a pacemaker.
    • Patients at higher risk of symptomatic bradycardia or heart block because of a coexisting medical condition or certain concomitant medications.
    • Patients randomized to the fingolimod arm with prolonged at screening (corrected QT interval > 450 ms in males and > 470 ms in females); for patients randomized to the fingolimod treatment arm before dosing (baseline) or during the 6-hour observation period; and those patients at additional risk for QT prolongation (e.g., hypokalemia, hypomagnesemia, congenital long-QT syndrome), or on a concomitant therapy with QT prolonging drugs with a known risk of Torsades de pointes (e.g., citalopram, chlorpromazine, haloperidol, methadone, erythromycin).
    • Patients receiving class Ia or Class III antiarrhythmic drugs (Appendix 6)
    • Patients receiving concurrent therapy with drugs that slow the heart rate or atrioventricular conduction (e.g., beta blockers, digoxin, or heart-rate slowing calcium channel blockers such as diltiazem, verapamil or digoxin). The possibility to switch to drugs that do not slow the heart rate or atrioventricular conduction should be evaluated by the physician prescribing these drugs before initiating fingolimod treatment.
    • History of sick sinus syndrome or sinoatrial heart block.
    • Resting heart rate of \< 45 bpm or symptomatic bradycardia
    • Recurrent syncope
    • Severe untreated sleep apnea
  16. Patients with severe pulmonary conditions (including severe respiratory disease, pulmonary fibrosis, active tuberculosis, severe or poorly controlled asthma).
  17. Patients with any of the following hepatic conditions:

    • Chronic liver or biliary disease
    • Total greater than (ULN) at screening unless in the context of Gilbert's syndrome
    • Conjugated bilirubin greater than the ULN at screening
    • (SGOT), ALT (SGPT) greater than 3 times ULN at screening
    • Alkaline phosphatase (AP) greater than 1.5 times the ULN at screening
  18. Serum creatinine greater than 2.0 mg/dL (176.5 µmol/L) at screening.
  19. Patients with the following neurological/psychiatric disorders:

    • History of substance abuse (drug or alcohol) in the past five years as determined by the investigator
    • Progressive neurological disorder other than MS which may affect study participation as determined by the investigator
    • Any serious psychiatric condition that may interfere with the patient's ability to cooperate and comply with the study procedures as determined by the investigator
  20. Women who are pregnant or nursing (lactating) or planning to become pregnant.
  21. Any condition that in the opinion of the investigator, would compromise the well-being of the patient or the conduct of the study, or prevent the patient from meeting or performing study requirements.
  22. Pre-planned surgery or medical procedure that would interfere with the conduct of the study.
  23. Employee of the sponsor, investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
881 participants (actual)

Study arms

  • Experimental
    Fingolimod

    Drug: Fingolimod

  • Active comparator
    Disease Modifying Therapy

    2 classes - Interferon Beta preparation (Exctavia, Betaseron, Rebif, Avonex) or glatiramer acetate (Copaxone)

    Drug: Disease Modifying therapy

Interventions

06

What researchers measure

Primary outcomes

  1. Participant Retention Rate Over 12 Months

    Comparison effectiveness of fingolimod versus approved first-line disease modifying therapies by measuring the rate of participant retention on randomized treatment over a 12-month period (Full analysis set)

    Time frame: at 12 months

Secondary outcomes

  1. Primary and Secondary Reasons for Discontinuation From Randomized Treatment: Randomized Set

    Reasons for discontinuation in participants treated with fingolimod vs. DMT over 12 months of treatment Total discontinued (Primary reason): Fingolimod arm: 27, MS-DMT arm: 27 = 54 participants Total discontinued (Secondary reason): Fingolimod arm: 257, MS-DMT arm: 256 = 513 participants Throughout the study, investigators evaluated each patient for occurrence of randomized treatment discontinuation and determined the primary and secondary reasons for such discontinuation. At every visit, the investigator evaluated the patients and determined if they should continue on randomized treatment or change to alternative treatment. Treatment discontinuation was a clinically meaningful measure related to safety, efficacy, and tolerability over time, reflecting the therapeutic effectiveness of study treatment.

    Time frame: at 12 months

  2. Change From Baseline of Symbol Digit Modalities Test (SDMT) Scores (Oral Test) by Visit (Randomized Treatment / Randomized Phase)

    Summary statistics Compare cognitive impairment measured by Symbol Digit Modalities Test (SDMT) scores. The SDMT score and its change from baseline value were summarized by visit. For the change from baseline values at each visit, ANCOVA adjusted for treatment naivety, corresponding baseline values, and age was performed for treatment comparisons The SDMT measures the time to pair abstract symbols with specific numbers. The test requires elements of attention, visuoperceptual processing, working memory, and psychomotor speed. The score is the number of correctly coded items from 0-110 in 90 seconds. The total score provides a measure of the speed and accuracy of symbol-digit substitution. NOTE: Higher scores indicate better performance.

    Time frame: baseline, 6 months, 12 months, and Last assessment which is either at Month 12 or at early discontinuation

  3. Change From Baseline of Symbol Digit Modalities Test (SDMT) Scores (Written Test) by Visit (Randomized Treatment / Randomized Phase)

    Summary statistics Compare cognitive impairment measured by Symbol Digit Modalities Test (SDMT) scores. The SDMT score and its change from baseline value were summarized by visit. For the change from baseline values at each visit, ANCOVA adjusted for treatment naivety, corresponding baseline values, and age was performed for treatment comparisons The SDMT measures the time to pair abstract symbols with specific numbers. The test requires elements of attention, visuoperceptual processing, working memory, and psychomotor speed. The score is the number of correctly coded items from 0-110 in 90 seconds. The total score provides a measure of the speed and accuracy of symbol-digit substitution. NOTE: Higher scores indicate better performance.

    Time frame: baseline, 6 months, 12 months, Last assessment which is either at Month 12 or at early discontinuation

  4. Percent Change From Baseline in Brain Volume From Month 12 to Last Visit (Randomized)

    Summary statistics for percent change from month 12 in brain volume by visit (Randomized treatment / randomized phase) in patients treated with fingolimod vs.DMTs as measured by MRI

    Time frame: 12 months, and Last assessment which is either at Month 12 or at early discontinuation

  5. Number of Satisfied Participants Per Medication Satisfaction Questionnaire (MSQ) Score

    Summary statistics for Medication Satisfaction Questionnaire\[Question: "Overall, how satisfied are you with your current medication?"\] (Randomized treatment / randomized phase): Fingolimod vs MS-DMT

    Time frame: Baseline, 1 month, 3 months, 6 months, 9 months, at 12 months & Last assessment during randomized phase which is either at Month 12 or at early discontinuation

07

Results

Posted Jan 12, 2018

Participant flow

62 Fingolimod arm participants discontinued: 57 discontinued before treatment switch, and 5 discontinued after treatment switch 100 MS-DMT arm participants discontinued before treatment switch: 57 discontinued before treatment switch, and 43 discontinued after treatment switch

Participant flow — Overall Study
MilestoneFingolimodDisease Modifying Therapy
Started436439
On randomized treatment352125
On switched treatment22214
Completed374339
Not completed62100
Withdrew: Abnormal laboratory values20
Withdrew: Administrative problems913
Withdrew: Adverse event2029
Withdrew: Death02
Withdrew: Lost to follow-up1216
Withdrew: Withdrawal by subject1331
Withdrew: Patient no longer requires study drug10
Withdrew: Protocol violation06
Withdrew: Lack of efficacy53

Outcome measures

PrimaryParticipant Retention Rate Over 12 Months

Comparison effectiveness of fingolimod versus approved first-line disease modifying therapies by measuring the rate of participant retention on randomized treatment over a 12-month period (Full analysis set)

Time frame:
at 12 months
Reported as:
Number · participants
Participant Retention Rate Over 12 Months
participantsFingolimodDisease Modifying Therapy (MS-DMT)
Participant Retention Rate Over 12 Months352125
SecondaryPrimary and Secondary Reasons for Discontinuation From Randomized Treatment: Randomized Set

Reasons for discontinuation in participants treated with fingolimod vs. DMT over 12 months of treatment Total discontinued (Primary reason): Fingolimod arm: 27, MS-DMT arm: 27 = 54 participants Total discontinued (Secondary reason): Fingolimod arm: 257, MS-DMT arm: 256 = 513 participants Throughout the study, investigators evaluated each patient for occurrence of randomized treatment discontinuation and determined the primary and secondary reasons for such discontinuation. At every visit, the investigator evaluated the patients and determined if they should continue on randomized treatment or change to alternative treatment. Treatment discontinuation was a clinically meaningful measure related to safety, efficacy, and tolerability over time, reflecting the therapeutic effectiveness of study treatment.

Time frame:
at 12 months
Reported as:
Number · participants
Primary and Secondary Reasons for Discontinuation From Randomized Treatment: Randomized Set
participantsFingolimodDisease Modifying Therapy (MS-DMT)
Occurrence of relapse (Primary reason)514
Disease activity present in MRI (Primary reason)06
Injection site reaction (Primary reason)061
Flu-like symptoms (Primary reason)034
Lipoatrophy (Primary reason)01
Depression (Primary reason)14
Hepatic side effects (Primary reason)73
Spasticity (Primary reason)01
Infection (Primary reason)00
Macular edema (Primary reason)10
Bradycardia (Primary reason)00
Needle phobia (Primary reason)013
Inconvenient administration (Primary reason)033
Frequency of injections (Primary reason)029
Neutralizing antibodies present (Primary reason)00
Other (Primary reason)1358
Occurrence of relapse (Secondary reason)03
Disease activity present in MRI (Secondary reason)25
Injection site reaction (Secondary reason)040
Flu-like symptoms (Secondary reason)116
Lipoatrophy (Secondary reason)01
Depression (Secondary reason)06
Hepatic side effects (Secondary reason)50
Spasticity (Secondary reason)12
Infection (Secondary reason)00
Macular edema (Secondary reason)10
Bradycardia (Secondary reason)00
Needle phobia (Secondary reason)018
Inconvenient administration (Secondary reason)055
Frequency of injections (Secondary reason)045
Neutralizing antibodies present (Secondary reason)00
Other (Secondary reason)1765
SecondaryChange From Baseline of Symbol Digit Modalities Test (SDMT) Scores (Oral Test) by Visit (Randomized Treatment / Randomized Phase)

Summary statistics Compare cognitive impairment measured by Symbol Digit Modalities Test (SDMT) scores. The SDMT score and its change from baseline value were summarized by visit. For the change from baseline values at each visit, ANCOVA adjusted for treatment naivety, corresponding baseline values, and age was performed for treatment comparisons The SDMT measures the time to pair abstract symbols with specific numbers. The test requires elements of attention, visuoperceptual processing, working memory, and psychomotor speed. The score is the number of correctly coded items from 0-110 in 90 seconds. The total score provides a measure of the speed and accuracy of symbol-digit substitution. NOTE: Higher scores indicate better performance.

Time frame:
baseline, 6 months, 12 months, and Last assessment which is either at Month 12 or at early discontinuation
Reported as:
Mean · SDMT score
Change From Baseline of Symbol Digit Modalities Test (SDMT) Scores (Oral Test) by Visit (Randomized Treatment / Randomized Phase)
SDMT scoreFingolimodDisease Modifying Therapy (MS-DMT)
Baseline (n=76,70)52.00 ± 12.1251.60 ± 13.40
Change at 6 months (n=70,64)2.20 ± 8.090.20 ± 10.13
Change at 12 months (n=58, 18)3.20 ± 7.091.40 ± 8.33
Change at Last assessment (n=73, 65)3.30 ± 7.770.40 ± 9.47
SecondaryChange From Baseline of Symbol Digit Modalities Test (SDMT) Scores (Written Test) by Visit (Randomized Treatment / Randomized Phase)

Summary statistics Compare cognitive impairment measured by Symbol Digit Modalities Test (SDMT) scores. The SDMT score and its change from baseline value were summarized by visit. For the change from baseline values at each visit, ANCOVA adjusted for treatment naivety, corresponding baseline values, and age was performed for treatment comparisons The SDMT measures the time to pair abstract symbols with specific numbers. The test requires elements of attention, visuoperceptual processing, working memory, and psychomotor speed. The score is the number of correctly coded items from 0-110 in 90 seconds. The total score provides a measure of the speed and accuracy of symbol-digit substitution. NOTE: Higher scores indicate better performance.

Time frame:
baseline, 6 months, 12 months, Last assessment which is either at Month 12 or at early discontinuation
Reported as:
Mean · SDMT score
Change From Baseline of Symbol Digit Modalities Test (SDMT) Scores (Written Test) by Visit (Randomized Treatment / Randomized Phase)
SDMT scoreFingolimodDisease Modifying Therapy (MS-DMT)
Baseline (n=355,348)48.90 ± 18.2648.50 ± 20.19
Change at 6 months (n=339,322)-0.50 ± 14.040.70 ± 13.16
Change at 12 months (n=282,105)0.70 ± 16.020.40 ± 14.90
Change at Last assessment (n=342, 324)0.80 ± 16.270.70 ± 13.95
SecondaryPercent Change From Baseline in Brain Volume From Month 12 to Last Visit (Randomized)

Summary statistics for percent change from month 12 in brain volume by visit (Randomized treatment / randomized phase) in patients treated with fingolimod vs.DMTs as measured by MRI

Time frame:
12 months, and Last assessment which is either at Month 12 or at early discontinuation
Reported as:
Mean · percent change in brain volume
Percent Change From Baseline in Brain Volume From Month 12 to Last Visit (Randomized)
percent change in brain volumeFingolimodDisease Modifying Therapy
Percent change at 12 months (n=323, 111)-0.396 ± 0.7825-0.555 ± 0.7181
Percent change at Last assessment (n=370, 246)-0.385 ± 0.7690-0.420 ± 0.6423
SecondaryNumber of Satisfied Participants Per Medication Satisfaction Questionnaire (MSQ) Score

Summary statistics for Medication Satisfaction Questionnaire\[Question: "Overall, how satisfied are you with your current medication?"\] (Randomized treatment / randomized phase): Fingolimod vs MS-DMT

Time frame:
Baseline, 1 month, 3 months, 6 months, 9 months, at 12 months & Last assessment during randomized phase which is either at Month 12 or at early discontinuation
Reported as:
Number · participants
Number of Satisfied Participants Per Medication Satisfaction Questionnaire (MSQ) Score
participantsFingolimodDisease Modifying Therapy (DS-DMT)
Baseline, Extremely dissatisfied10 ± 4.716 ± 7.2
Baseline, Very dissatisfied22 ± 10.313 ± 5.8
Baseline, Somewhat dissatisfied29 ± 13.639 ± 17.5
Baseline, Neither dissatisfied nor satisfied62 ± 29.061 ± 27.4
Baseline, Somewhat satisfied35 ± 16.446 ± 20.6
Baseline, Very satisfied42 ± 19.631 ± 13.9
Baseline, Extremely satisfied14 ± 6.517 ± 7.6
Baseline, Missing219 ± 0205 ± 0
1 month, Extremely dissatisfied8 ± 1.929 ± 6.9
1 month, Very dissatisfied14 ± 3.337 ± 8.9
1 month, Somewhat dissatisfied8 ± 1.952 ± 12.4
1 month, Neither dissatisfied nor satisfied32 ± 7.574 ± 17.7
1 month, Somewhat satisfied52 ± 12.189 ± 21.3
1 month, Very satisfied161 ± 37.597 ± 23.2
1 month, Extremely satisfied154 ± 35.940 ± 9.6
1 month, Missing4 ± 010 ± 0
3 months, Extremely dissatisfied5 ± 1.219 ± 5.5
3 months, Very dissatisfied11 ± 2.738 ± 11.0
3 months, Somewhat dissatisfied11 ± 2.742 ± 12.1
3 months, Neither dissatisfied nor satisfied46 ± 11.153 ± 15.3
3 months, Somewhat satisfied43 ± 10.473 ± 21.1
3 months, Very satisfied153 ± 37.091 ± 26.3
3 months, Extremely satisfied144 ± 34.930 ± 8.7
3 months, Missing20 ± 082 ± 0
6 months, Extremely dissatisfied8 ± 2.09 ± 4.6
6 months, Very dissatisfied15 ± 3.811 ± 5.6
6 months, Somewhat dissatisfied11 ± 2.813 ± 6.6
6 months, Neither dissatisfied nor satisfied25 ± 6.324 ± 12.2
6 months, Somewhat satisfied57 ± 14.446 ± 23.5
6 months, Very satisfied130 ± 32.767 ± 34.2
6 months, Extremely satisfied151 ± 38.026 ± 13.3
6 months, Missing36 ± 0232 ± 0
9 months, Extremely dissatisfied7 ± 1.94 ± 2.6
9 months, Very dissatisfied8 ± 2.26 ± 3.9
9 months, Somewhat dissatisfied12 ± 3.212 ± 7.8
9 months, Neither dissatisfied nor satisfied21 ± 5.715 ± 9.8
9 months, Somewhat satisfied42 ± 11.429 ± 19.0
9 months, Very satisfied135 ± 36.558 ± 37.9
9 months, Extremely satisfied145 ± 39.229 ± 19.0
9 months, Missing63 ± 0275 ± 0
12 months, Extremely dissatisfied7 ± 2.03 ± 2.4
12 months, Very dissatisfied7 ± 2.04 ± 3.1
12 months, Somewhat dissatisfied11 ± 3.14 ± 3.1
12 months, Neither dissatisfied nor satisfied27 ± 7.78 ± 6.3
12 months, Somewhat satisfied34 ± 9.722 ± 7.3
12 months, Very satisfied115 ± 32.860 ± 47.2
12 months, Extremely satisfied150 ± 42.726 ± 20.5
12 months, Missing82 ± 0301 ± 0
Last assessment, Extremely dissatisfied14 ± 3.346 ± 10.9
Last assessment, Very dissatisfied15 ± 3.561 ± 14.5
Last assessment, Somewhat dissatisfied23 ± 5.357 ± 13.5
Last assessment,Neither dissatisfied nor satisfied45 ± 10.558 ± 13.7
Last assessment, Somewhat satisfied43 ± 10.069 ± 16.4
Last assessment, Very satisfied128 ± 29.894 ± 22.3
Last assessment, Extremely satisfied162 ± 37.737 ± 8.8
Last assessment, Missing3 ± 06 ± 0

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fingolimod—29/433 (6.7%)282/433 (65.1%)
MS DMT—15/428 (3.5%)291/428 (68%)
Most frequent serious events
Showing 10 of 65
Most frequent serious events
EventFingolimodMS DMT
Multiple sclerosis relapseNervous system disorders5/4335/428
AnxietyPsychiatric disorders1/4332/428
PneumoniaInfections and infestations2/4330/428
DehydrationMetabolism and nutrition disorders2/4330/428
Suicidal ideationPsychiatric disorders2/4330/428
LeukocytosisBlood and lymphatic system disorders0/4331/428
Cardio-respiratory arrestCardiac disorders0/4331/428
Abdominal painGastrointestinal disorders0/4331/428
Gastrooesophageal reflux diseaseGastrointestinal disorders0/4331/428
Umbilical herniaGastrointestinal disorders0/4331/428
Most frequent other events
Showing 10 of 25
Most frequent other events
EventFingolimodMS DMT
Influenza like illnessGeneral disorders12/43364/428
Injection site painGeneral disorders0/43362/428
Injection site reactionGeneral disorders0/43350/428
FatigueGeneral disorders49/43333/428
Injection site erythemaGeneral disorders0/43342/428
HeadacheNervous system disorders40/43341/428
NasopharyngitisInfections and infestations41/43322/428
DizzinessNervous system disorders31/43312/428
Injection site pruritusGeneral disorders0/43330/428
LymphopeniaBlood and lymphatic system disorders30/4331/428

Baseline characteristics

Randomized set (RS): consists of all patients who were assigned randomization numbers. The participants in this set were called randomized participants. This set was used to summarize participant disposition, demographic and baseline characteristics, and protocol deviation information. Participants were grouped according to randomized treatment.

Age, Continuous
Age, Continuous(years)FingolimodDisease Modifying Therapy (MS_DMT)Total
Mean41.5 ± 10.8441.9 ± 10.3941.7 ± 10.61
Sex: Female, Male
Sex: Female, Male(Participants)FingolimodDisease Modifying Therapy (MS_DMT)Total
Female311329640
Male125110235
08

Study locations

123 sites
  • Novartis Investigative Site
    Cullman, Alabama 35058, United States
  • Novartis Investigative Site
    Phoenix, Arizona 85004, United States
  • Novartis Investigative Site
    Sun City, Arizona 85351, United States
  • Novartis Investigative Site
    Tucson, Arizona 85741, United States
  • Novartis Investigative Site
    Sherwood, Arkansas 72120, United States
  • Novartis Investigative Site
    Fullerton, California 92835, United States
  • Novartis Investigative Site
    Oceanside, California 92056, United States
  • Novartis Investigative Site
    San Francisco, California 94117, United States
  • Novartis Investigative Site
    Walnut Creek, California 94598, United States
  • Novartis Investigative Site
    Basalt, Colorado 81621, United States
  • Novartis Investigative Site
    Boulder, Colorado 80301, United States
  • Novartis Investigative Site
    Denver, Colorado 80209, United States
  • Novartis Investigative Site
    Denver, Colorado 80210, United States
  • Novartis Investigative Site
    Fort Collins, Colorado 80528, United States
  • Novartis Investigative Site
    Fairfield, Connecticut 06824, United States
  • Novartis Investigative Site
    New London, Connecticut 06320, United States
  • Novartis Investigative Site
    Dover, Delaware 19901, United States
  • Novartis Investigative Site
    Atlantis, Florida 33462-6608, United States
  • Novartis Investigative Site
    Bradenton, Florida 34205, United States
  • Novartis Investigative Site
    Delray Beach, Florida 33445, United States
  • Novartis Investigative Site
    Hollywood, Florida 33021, United States
  • Novartis Investigative Site
    Jacksonville, Florida 32216, United States
  • Novartis Investigative Site
    North Palm Beach, Florida 33408, United States
  • Novartis Investigative Site
    Plantation, Florida 33324, United States
  • Novartis Investigative Site
    Pompano Beach, Florida 33060, United States
  • Novartis Investigative Site
    Port Charlotte, Florida 33952, United States
  • Novartis Investigative Site
    Port Orange, Florida 32127, United States
  • Novartis Investigative Site
    Saint Petersburg, Florida 33713, United States
  • Novartis Investigative Site
    Sarasota, Florida 34233, United States
  • Novartis Investigative Site
    Sarasota, Florida 34243, United States
  • Novartis Investigative Site
    Tallahassee, Florida 32308, United States
  • Novartis Investigative Site
    Tampa, Florida 33609, United States
  • Novartis Investigative Site
    West Palm Beach, Florida 33407, United States
  • Novartis Investigative Site
    Atlanta, Georgia 30312, United States
  • Novartis Investigative Site
    Columbus, Georgia 31904, United States
  • Novartis Investigative Site
    Decatur, Georgia 30083, United States
  • Novartis Investigative Site
    Suwanee, Georgia 30024, United States
  • Novartis Investigative Site
    Flossmoor, Illinois 60422, United States
  • Novartis Investigative Site
    Northbrook, Illinois 60062, United States
  • Novartis Investigative Site
    Anderson, Indiana 46011, United States
  • Novartis Investigative Site
    Indianapolis, Indiana 46227, United States
  • Novartis Investigative Site
    Indianapolis, Indiana 46256, United States
  • Novartis Investigative Site
    Des Moines, Iowa 50314-2611, United States
  • Novartis Investigative Site
    Overland Park, Kansas, United States
  • Novartis Investigative Site
    Wichita, Kansas 67214, United States
  • Novartis Investigative Site
    Hawesville, Kentucky 42384, United States
  • Novartis Investigative Site
    Lexington, Kentucky 40504, United States
  • Novartis Investigative Site
    Madisonville, Kentucky 42431, United States
  • Novartis Investigative Site
    Alexandria, Louisiana 71301, United States
  • Novartis Investigative Site
    Baton Rouge, Louisiana 70809, United States
  • Novartis Investigative Site
    New Orleans, Louisiana 70115, United States
  • Novartis Investigative Site
    Annapolis, Maryland 21401, United States
  • Novartis Investigative Site
    Fulton, Maryland 20759, United States
  • Novartis Investigative Site
    New Bedford, Massachusetts 02740, United States
  • Novartis Investigative Site
    North Dartmouth, Massachusetts 02747, United States
  • Novartis Investigative Site
    Springfield, Massachusetts 01104, United States
  • Novartis Investigative Site
    Watertown, Massachusetts 02472, United States
  • Novartis Investigative Site
    Worcester, Massachusetts 01608, United States
  • Novartis Investigative Site
    Kalamazoo, Michigan 49007, United States
  • Novartis Investigative Site
    Traverse City, Michigan 49684-2340, United States
  • Novartis Investigative Site
    Nixa, Missouri 65714-7807, United States
  • Novartis Investigative Site
    North Kansas City, Missouri 64116, United States
  • Novartis Investigative Site
    Saint Louis, Missouri 63104, United States
  • Novartis Investigative Site
    Las Vegas, Nevada 89121, United States
  • Novartis Investigative Site
    Las Vegas, Nevada 89123, United States
  • Novartis Investigative Site
    Las Vegas, Nevada 89144, United States
  • Novartis Investigative Site
    Flemington, New Jersey 08822, United States
  • Novartis Investigative Site
    Teaneck, New Jersey 07666, United States
  • Novartis Investigative Site
    Toms River, New Jersey 08755, United States
  • Novartis Investigative Site
    Albuquerque, New Mexico 87108, United States
  • Novartis Investigative Site
    Albany, New York 12208, United States
  • Novartis Investigative Site
    Amherst, New York 14226, United States
  • Novartis Investigative Site
    Bronx, New York 10467-2490, United States
  • Novartis Investigative Site
    Kingston, New York 12401, United States
  • Novartis Investigative Site
    Latham, New York 12110, United States
  • Novartis Investigative Site
    New York, New York 10003, United States
  • Novartis Investigative Site
    Patchogue, New York 11772, United States
  • Novartis Investigative Site
    Asheville, North Carolina 28806, United States
  • Novartis Investigative Site
    Charlotte, North Carolina 28202, United States
  • Novartis Investigative Site
    Charlotte, North Carolina 28204, United States
  • Novartis Investigative Site
    Greensboro, North Carolina 27401, United States
  • Novartis Investigative Site
    Greenville, North Carolina 27834, United States
  • Novartis Investigative Site
    Raleigh, North Carolina 27607, United States
  • Novartis Investigative Site
    Salisbury, North Carolina 28144, United States
  • Novartis Investigative Site
    Winston-Salem, North Carolina 27103, United States
  • Novartis Investigative Site
    Grand Forks, North Dakota 58201, United States
  • Novartis Investigative Site
    Akron, Ohio 44320, United States
  • Novartis Investigative Site
    Bellevue, Ohio 44811, United States
  • Novartis Investigative Site
    Canton, Ohio 44718, United States
  • Novartis Investigative Site
    Cincinnati, Ohio 45219, United States
  • Novartis Investigative Site
    Columbus, Ohio 43221, United States
  • Novartis Investigative Site
    Dayton, Ohio 45408, United States
  • Novartis Investigative Site
    Toledo, Ohio 43623, United States
  • Novartis Investigative Site
    Oklahoma City, Oklahoma 73104, United States
  • Novartis Investigative Site
    Oklahoma City, Oklahoma 73112, United States
  • Novartis Investigative Site
    Eugene, Oregon 97401, United States
  • Novartis Investigative Site
    Greensburg, Pennsylvania 15601, United States
  • Novartis Investigative Site
    Hershey, Pennsylvania 17033-0850, United States
  • Novartis Investigative Site
    Pittsburgh, Pennsylvania 15212, United States
  • Novartis Investigative Site
    Cranston, Rhode Island 02920, United States

Showing the first 100 of 123 sites across 2 countries. Choose a country and city above to see the rest.

09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2012 to primary completion in Jul 2015, 37 months.

Results were first posted in Jan 2018, 2 years 5 months after primary completion.

Of 28 phase 4 interventional studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 66. This study's 37 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2012
First posted
Jun 20, 2012
StartActual
Jun 8, 2012
Primary completionActual
Jul 13, 2015
CompletionActual
Jul 13, 2015
Results first posted
Jan 12, 2018
Last update
Jan 5, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01623596
Responsible party
Sponsor
First posted
Jun 20, 2012
Start date
Jun 8, 2012
Primary completion
Jul 13, 2015
Completion
Jul 13, 2015
Results posted
Jan 12, 2018
Last update
Jan 5, 2021

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fingolimod

Start the discussion